22nd Century Group (Nasdaq: XXII) has acquired GVB Biopharma. Read the press release here
1. Facilitating Smoking Cessation With Reduced Nicotine Cigarettes
ClinicalTrials.gov Identifier: NCT02796391
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Collaborator: James and Esther King Biomedical Research Program
2. Novel Approaches to Reducing Tobacco Related Harm
ClinicalTrials.gov Identifier: NCT02600273
Sponsor: Duke University
Collaborator: National Institute of Allergy and Infectious Diseases (NIAID)
3. Abuse Liability of Reduced Nicotine Content Cigarettes in the Context of Concurrent E-Cigarette Use
ClinicalTrials.gov Identifier: NCT02870218
Sponsor: Rose Research Center, LLC
Collaborators: National Institutes of Health (NIH) and Food and Drug Administration (FDA)
4. Effects of Nicotine Reduction on Smoking Behavior in ADHD Smokers
ClinicalTrials.gov Identifier: NCT02599571
Sponsor: Duke University
Collaborators: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Food and Drug Administration (FDA), and University of Pittsburgh
5. Evaluation of Very Low Nicotine Content Cigarettes in Adolescent Smokers
ClinicalTrials.gov Identifier: NCT02587312
Sponsor: Brown University
Collaborator: National Cancer Institute (NCI)
6. Manipulating Tobacco Constituents in Female Menthol Smokers
ClinicalTrials.gov Identifier: NCT02048852
Sponsor: University of Connecticut Health Center
Collaborator: National Institute on Drug Abuse (NIDA)
7. Manipulating Tobacco Constituents in Male Menthol Smokers
ClinicalTrials.gov Identifier: NCT02592772
Sponsor: University of Connecticut Health Center
Collaborator: National Institute on Drug Abuse (NIDA)
8. Project 1, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in Childbearing Age Women
ClinicalTrials.gov Identifier: NCT02250534
Sponsor: University of Vermont
Collaborators: National Institute on Drug Abuse (NIDA) and Johns Hopkins University
9. Project 1, Study 2: The Combined Impact of Nicotine Replacement and Spectrum Cigarettes
ClinicalTrials.gov Identifier: NCT02301325
Sponsor: University of Pittsburgh
10. Project 2, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in Opioid Abusers
ClinicalTrials.gov Identifier: NCT02250664
Sponsor: University of Vermont
Collaborators: National Institute on Drug Abuse (NIDA) and Johns Hopkins University
11. Project 3, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in People With Current Affective Disorders
ClinicalTrials.gov Identifier: NCT02232737
Sponsor: Brown University
Collaborator: University of Vermont
12. Reduced Nicotine Content Cigarettes in Smokers of Lower Socioeconomic Status
ClinicalTrials.gov Identifier: NCT01928719
Sponsor: Milton S. Hershey Medical Center
Collaborator: George Washington University
13. Reduced Nicotine Cigarettes in Smokers With Mood and Anxiety Disorders
ClinicalTrials.gov Identifier: NCT01928758
Sponsor: Milton S. Hershey Medical Center
Collaborator: National Institute on Drug Abuse (NIDA)
14. Strengthening Instrumental Extinction to Prevent Smoking Relapse (VLNCCue)
ClinicalTrials.gov Identifier: NCT02538042
Sponsor: Francis McClernon
Collaborators: National Institutes of Health (NIH) and National Institute on Drug Abuse (NIDA)
15. Switching to Reduced Oxidant or Nicotine Content Cigarettes in Smokers
ClinicalTrials.gov Identifier: NCT02415270
Sponsor: Milton S. Hershey Medical Center
Collaborators: Food and Drug Administration (FDA), National Institutes of Health (NIH), and National Institute on Drug Abuse (NIDA)
16. Very-Low Nicotine Cigarettes and Non-Daily Smokers
ClinicalTrials.gov Identifier: NCT02228824
Sponsor: University of Pittsburgh
Collaborator: National Cancer Institute (NCI)
17. Very Low Nicotine Cigarettes in Smokers With Schizophrenia
ClinicalTrials.gov Identifier: NCT02019459
Sponsor: Brown University
Collaborators: National Institute on Drug Abuse (NIDA) and University of Pittsburgh
18. Very Low-Nicotine Cigarettes in Smokers With SUD
ClinicalTrials.gov Identifier: NCT01989507
Sponsor/Collaborator: Brown University
19. Neuroimaging Reward, Behavioral Treatment, and Smoking Cessation
ClinicalTrials.gov Identifier: NCT02927847
Sponsor: Maggie M. Sweitzer, PhD
Collaborator: National Institute on Drug Abuse (NIDA)
20. Abuse Liability of Reduced Nicotine Content Cigarettes Within a Complex Tobacco Marketplace: Experiment 1
ClinicalTrials.gov Identifier: NCT02951143
Sponsor: Virginia Polytechnic Institute and State University
21. Concomitant Use of Very Low Nicotine Content Cigarettes and e-Cigarettes
ClinicalTrials.gov Identifier: NCT02964182
Sponsor: M.D. Anderson Cancer Center
Collaborator: National Institute on Drug Abuse (NIDA)
22. Reactions to Reduced Nicotine Cigarettes in Young Adult Low-Frequency Smokers (NicRed)
ClinicalTrials.gov Identifier: NCT02989038
Sponsor: Duke University
Collaborator: National Institute on Drug Abuse (NIDA)
23. Reduced Nicotine Cigarettes in Smokers With and Without Alcohol Use Disorder (RedNic)
ClinicalTrials.gov Identifier: NCT02990455
Sponsor: Battelle Memorial Institute
24. Switching to Very Low Nicotine Content Cigarettes vs Reducing Cigarettes Per Day
ClinicalTrials.gov Identifier: NCT03060083
Sponsor: University of Vermont
25. A Study to Assess Changes in Cigarette Consumption During a Switch to Very Low Nicotine Cigarettes
ClinicalTrials.gov Identifier: NCT03571724
Sponsor: 22nd Century Group, Inc.
Collaborator: Celerion
26. Evaluation of the Abuse Liability of Very Low Nicotine (VLNC) Cigarettes
ClinicalTrials.gov Identifier: NCT03559751
Sponsor: 22nd Century Group, Inc.
Collaborator: Vince & Associates Clinical Research, Inc.
27. Evaluation of Abuse Liability of Very Low Nicotine (VLNC) Mentholated Cigarettes
ClinicalTrials.gov Identifier: NCT03559725
Sponsor: 22nd Century Group, Inc.
Collaborator: Vince & Associates Clinical Research, Inc.